Kenneth Tew, PhD, DSc
Professor and Chairman
John C. West Chair of Cancer Research
Program Leader - Developmental Cancer Therapeutics Program
Hollings Cancer Center
1976 Ph.D., University of London
1995 D.Sc., Institute of Cancer Research
Office: DD413 & BSB 358
Cancer Drug Development
The development of novel drugs remains a high priority in the successful therapeutic management of cancer. We have applied our accumulated knowledge of glutathione and glutathione S-transferases to the design and testing of new drugs that target glutathione pathways. In collaboration with industrial sector colleagues, a GST activated prodrug is now in late stage clinical testing. In addition, a small molecule peptidomimetic myeloproliferative agent is presently in early clinical testing in myelodysplastic syndrome. We continue to work on the molecular and biochemical mechanisms of these drugs and to elucidate cellular pathways that impact upon drug response and resistance.
Other efforts focus upon the elucidation of the function of a novel human membrane transporter, ABCA2. Continuing studies suggest that cholesterol trafficking may be controlled by this transporter. Its role in human disease states may serve as a prelude to targeting it for therapeutic intervention.
Recent Publications | Additional Publications
1. Zhang J, Grek C, Ye ZW, Manevich Y, Tew KD, Townsend DM. Pleiotropic functions of glutathione s-transferase p. Adv Cancer Res. 2014;122:143-75
2. Manevich Y, Hutchens S, Halushka PV, Tew KD, Townsend DM, Jauch EC, Borg K. Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome. Free Radic Biol Med. 2014 Jul;72:210-21.
3. Grek CL, Zhang J, Manevich Y, Townsend DM, Tew KD. Causes and consequences of cysteine S-glutathionylation. J Biol Chem. 2013 Sep 13;288(37):26497-504.
4. Manevich Y, Hutchens S, Tew KD, Townsend DM. Allelic variants of glutathione S-transferase P1-1 differentially mediate the peroxidase function of peroxiredoxin VI and alter membrane lipid peroxidation. Free Radic Biol Med. 2013 Jan;54:62-70.
5. Bowers RR, Manevich Y, Townsend DM, Tew KD. Sulfiredoxin redox-sensitive interaction with S100A4 and non-muscle myosin IIA regulates cancer cell motility. Biochemistry. 2012 Oct 2;51(39):7740-54.
6. Mack JT, Brown CB, Garrett TE, Uys JD, Townsend DM, Tew KD. Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies. Biomed Pharmacother. 2012 Sep;66(6):403-8.
7. Grünewald E, Tew KD, Porteous DJ, Thomson PA. Developmental expression of orphan G protein-coupled receptor 50 in the mouse brain. ACS Chem Neurosci. 2012 Jun 20;3(6):459-72.
8. Anathy V, Roberson E, Cunniff B, Nolin JD, Hoffman S, Spiess P, Guala AS, Lahue KG, Goldman D, Flemer S, van der Vliet A, Heintz NH, Budd RC, Tew KD, Janssen-Heininger YM. Oxidative processing of latent Fas in the endoplasmic reticulum controls the strength of apoptosis. Mol Cell Biol. 2012 Sep;32(17):3464-78.